Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Diabetes, Diabetes Mellitus, Type 2
Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial was conducted in Russian Federation. This trial aimed for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different treatment regimens: biphasic insulin aspart 30 thrice daily…
- Trial name
- NCT00280046
- Testing
- biphasic insulin aspart
- Where
- 11 sites in Russia
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.
- Trial name
- NCT01865474
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 122 people
- Sponsor
- Dexa Medica Group
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes, Endocrine, Nutritional and Metabolic Diseases (E00-E89)
COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy
The purpose of this research study is to collect information about a new treatment for Type 2 Diabetes Mellitus (T2DM), using a medical device called the Metabolic Neuromodulation System which is intended to help regulate blood…
- Trial name
- NCT02278068
- Testing
- Metabolic Neuromodulation System (MNS)
- Where
- 6 sites in New Zealand
- Volunteers
- 46 people
- Sponsor
- Metavention
Type 2 Diabetes
A Study of HS-20094 in T2DM Participants
This is a randomized, placebo and active-control, multiple-dose, phase IIa trial. Patients were randomly assigned to receive HS-20094 (12 patients), placebo (3 patients), or active control drug Semaglutide injection (3 patients)…
- Trial name
- NCT06118008
- Testing
- HS-20094 5mg, HS-20094 10mg, HS-20094 15mg
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes
The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT02588950
- Testing
- U-500R
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
- Trial name
- NCT01664624
- Testing
- Roflumilast, Alogliptin, Exenatide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin…
- Trial name
- EasyMix (NCT01123980)
- Testing
- biphasic insulin aspart 30, metformin, glimepiride
- Where
- 34 sites in China, Japan
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects
This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.
- Trial name
- NCT06422039
- Testing
- HRS-7535(D) Tablets, HRS-7535(C) Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes, Obesity
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
The purpose of the registry was to observe the safety and effectiveness outcomes for subjects treated with the EndoBarrier in the post market setting where the product had Conformité Européene (CE mark) regulatory approval and in…
- Trial name
- NCT03072901
- Testing
- EndoBarrier Gastrointestinal Liner
- Volunteers
- 244 people
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Primary Objective: To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).
- Trial name
- LixiRam (NCT02941367)
- Testing
- Lixisenatide (AVE0010), Sulfonylurea, metformin
- Where
- 16 sites in India, Israel and 2 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
The purpose of this study is to assess the safety, tolerability, and efficacy of the addition of canagliflozin relative to the addition of placebo in patients with inadequate glycemic control on metformin alone or in combination…
- Trial name
- NCT01381900
- Testing
- Canagliflozin 100mg, Canagliflozin 300mg, Metformin
- Where
- 25 sites in China, Malaysia and 1 more
- Volunteers
- 678 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy
- Trial name
- NCT04465877
- Testing
- JTT-662
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Shionogi Inc.
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd
Type 2 Diabetes Mellitus
Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.
- Trial name
- NCT01101945
- Testing
- dutogliptin
- Where
- 55 sites in United States, Argentina and 3 more
- Volunteers
- 339 people
- Sponsor
- Phenomix
Type 2 Diabetes
Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM
This research study is being done to evaluate the effect of hepatic ultrasound insonification on whole-body insulin sensitivity and evaluate the safety and tolerability of hepatic ultrasound insonification in subjects with Type 2…
- Trial name
- NCT04502212
- Testing
- Hepatic Ultrasound Insonification
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- General Electric Research